Free Trial

Chemomab Therapeutics (CMMB) Insider Trading & Ownership

Chemomab Therapeutics logo
$1.58 -0.06 (-3.60%)
(As of 02:58 PM ET)

Chemomab Therapeutics (NASDAQ:CMMB) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.91%
Number Of
Insiders Buying
(Last 3 Years)
4
Amount Of
Insider Buying
(Last 3 Years)
$61,935.00
Number Of
Insiders Selling
(Last 3 Years)
3
Amount Of
Insider Selling
(Last 3 Years)
$1.89 M
Get CMMB Insider Trade Alerts

Want to know when executives and insiders are buying or selling Chemomab Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

CMMB Insider Buying and Selling by Quarter

Chemomab Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2023Israel Gp Ltd. OrbimedMajor ShareholderSell336,900$3.58$1,206,102.00  
11/16/2022George Adi MorInsiderSell324,775$2.08$675,532.00  
11/16/2022Neil Harris CohenDirectorSell2,409$2.00$4,818.00  
3/18/2022Joel Michael MarylesDirectorBuy1,000$4.34$4,340.00  
3/16/2022Donald MarvinCFOBuy500$3.27$1,635.00  
3/14/2022Dale R PfostCEOBuy2,500$3.98$9,950.00  
3/14/2022Donald MarvinCFOBuy1,250$4.04$5,050.00  
3/14/2022Neil Harris CohenDirectorBuy6,000$4.35$26,100.00  
12/6/2021Neil Harris CohenDirectorBuy2,000$7.43$14,860.00  
(Data available from 1/1/2013 forward)

CMMB Insider Trading Activity - Frequently Asked Questions

The list of insiders at Chemomab Therapeutics includes Dale R Pfost, Donald Marvin, George Adi Mor, Israel Gp Ltd. Orbimed, Joel Michael Maryles, and Neil Harris Cohen. Learn more on insiders at CMMB.

11.91% of Chemomab Therapeutics stock is owned by insiders. Learn more on CMMB's insider holdings.

The following insider sold CMMB shares in the last 24 months: Israel Gp Ltd. Orbimed ($1,206,102.00).

Insiders have sold a total of 336,900 Chemomab Therapeutics shares in the last 24 months for a total of $1,206,102.00 sold.

Chemomab Therapeutics Key Executives

  • Dr. Adi Mor George Ph.D. (Age 42)
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
    Compensation: $330k
  • Ms. Sigal Fattal CPA (Age 53)
    M.B.A., Chief Financial Officer
    Compensation: $322k
  • Dr. Matthew B. Frankel M.B.A. (Age 55)
    M.D., Chief Medical Officer & VP of Drug Development
    Compensation: $850k
  • Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications


This page (NASDAQ:CMMB) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners